Histogenics (HSGX) Reaches $2.86 After 4.00% Up Move; GAM HOLDING AG ORDINARY SHARES NAMEN AKT (GMHLF) Shorts Decreased By 5.03%

June 14, 2018 - By Peter Erickson

Histogenics Corporation (NASDAQ:HSGX) Logo

GAM HOLDING AG ORDINARY SHARES NAMEN AKT (OTCMKTS:GMHLF) had a decrease of 5.03% in short interest. GMHLF’s SI was 608,300 shares in June as released by FINRA. Its down 5.03% from 640,500 shares previously. With 300 avg volume, 2028 days are for GAM HOLDING AG ORDINARY SHARES NAMEN AKT (OTCMKTS:GMHLF)’s short sellers to cover GMHLF’s short positions. The SI to GAM HOLDING AG ORDINARY SHARES NAMEN AKT’s float is 0.41%. It closed at $15.260642 lastly. It is down 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

The stock of Histogenics Corporation (NASDAQ:HSGX) is a huge mover today! The stock increased 5.01% or $0.14 during the last trading session, reaching $2.86. About 71,806 shares traded. Histogenics Corporation (NASDAQ:HSGX) has risen 41.82% since June 14, 2017 and is uptrending. It has outperformed by 29.25% the S&P500. Some Historical HSGX News: ; 15/03/2018 – HISTOGENICS CORP – QTRLY NET LOSS PER COMMON SHARE $0.26; 15/03/2018 – Histogenics 4Q Loss/Shr 26c; 10/05/2018 – Histogenics 1Q Loss/Shr 52c; 10/05/2018 – Histogenics 1Q Rev $0.00; 15/03/2018 – Histogenics 4Q Rev $0.00; 31/05/2018 – Histogenics Corporation to Host Investor Day on June 19, 2018; 18/04/2018 – Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors; 22/04/2018 – DJ Histogenics Corp, Inst Holders, 1Q 2018 (HSGX); 10/05/2018 – Histogenics 1Q Loss $14.4M; 15/03/2018 HISTOGENICS CORP – EXPECTS TOTAL OPERATING EXPENSES OF BETWEEN $29 MLN AND $31 MLN FOR YEAR ENDING DECEMBER 31, 2018The move comes after 9 months positive chart setup for the $81.94M company. It was reported on Jun, 14 by Barchart.com. We have $2.97 PT which if reached, will make NASDAQ:HSGX worth $3.28M more.

GAM Holding AG is a publicly owned asset management holding company. The company has market cap of $2.32 billion. Through its subsidiaries, the firm manages separate client focused equity and fixed income portfolios. It has a 19.29 P/E ratio. Through its subsidiaries, it also launches and manages equity, fixed income, and balanced mutual funds.

Among 6 analysts covering Histogenics Corp (NASDAQ:HSGX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Histogenics Corp has $15 highest and $3.5000 lowest target. $6.30’s average target is 120.28% above currents $2.86 stock price. Histogenics Corp had 18 analyst reports since August 27, 2015 according to SRatingsIntel. H.C. Wainwright maintained Histogenics Corporation (NASDAQ:HSGX) rating on Thursday, November 2. H.C. Wainwright has “Buy” rating and $3.5 target. The stock has “Buy” rating by Canaccord Genuity on Friday, November 13. H.C. Wainwright initiated it with “Buy” rating and $3.50 target in Monday, December 19 report. The firm earned “Buy” rating on Friday, August 12 by BTIG Research. Canaccord Genuity maintained the shares of HSGX in report on Thursday, December 21 with “Buy” rating. The firm earned “Market Perform” rating on Wednesday, September 7 by William Blair. Canaccord Genuity maintained the stock with “Buy” rating in Monday, October 16 report. The rating was maintained by H.C. Wainwright with “Buy” on Monday, March 19. As per Friday, November 13, the company rating was downgraded by BTIG Research. On Friday, November 13 the stock rating was maintained by Needham with “Buy”.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $81.94 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

Histogenics Corporation (NASDAQ:HSGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.